Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain D Baron

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Endocrinology|August 29, 2006
Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expressionJonathan D Roth, Heather Hughes, Eric Kendall, et al.
The Journal of Clinical Endocrinology and Metabolism|February 8, 2003
Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndromeGiancarlo Paradisi, Helmut O Steinberg, Marguerite K Shepard, et al.
Cardiovascular Diabetology|August 4, 2010
The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive ratsQue Liu, Lisa Adams, Anatoly Broyde, et al.
Obesity Research|April 19, 2005
Insulin and endothelin in the acute regulation of adiponectin in vivo in humansLori A Brame, Robert V Considine, Mikako Yamauchi, et al.
Diabetes/Metabolism Research and Reviews|September 3, 2004
Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetesMark S Fineman, Larry Z Shen, Kristin Taylor, et al.
Diabetes Care|October 27, 2004
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetesJohn B Buse, Robert R Henry, Jenny Han, et al.
Diabetes Care|April 28, 2005
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetesRalph A DeFronzo, Robert E Ratner, Jenny Han, et al.
American Journal of Physiology. Endocrinology and Metabolism|October 30, 2008
Hyperinsulinemia fails to augment ET-1 action in the skeletal muscle vascular bed in vivo in humansAmale A Lteif, Angie D Fulford, Robert V Considine, et al.
Diabetes/Metabolism Research and Reviews|May 8, 2002
Role of amylin in insulin secretion and action in humans: antagonist studies across the spectrum of insulin sensitivityKieren J Mather, Giancarlo Paradisi, Rosalind Leaming, et al.
Diabetes Care|April 28, 2005
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylureaDavid M Kendall, Matthew C Riddle, Julio Rosenstock, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Endocrinology|August 29, 2006
Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expressionJonathan D Roth, Heather Hughes, Eric Kendall, et al.
The Journal of Clinical Endocrinology and Metabolism|February 8, 2003
Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndromeGiancarlo Paradisi, Helmut O Steinberg, Marguerite K Shepard, et al.
Cardiovascular Diabetology|August 4, 2010
The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive ratsQue Liu, Lisa Adams, Anatoly Broyde, et al.
Obesity Research|April 19, 2005
Insulin and endothelin in the acute regulation of adiponectin in vivo in humansLori A Brame, Robert V Considine, Mikako Yamauchi, et al.
Diabetes/Metabolism Research and Reviews|September 3, 2004
Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetesMark S Fineman, Larry Z Shen, Kristin Taylor, et al.
Diabetes Care|October 27, 2004
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetesJohn B Buse, Robert R Henry, Jenny Han, et al.
Diabetes Care|April 28, 2005
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetesRalph A DeFronzo, Robert E Ratner, Jenny Han, et al.
American Journal of Physiology. Endocrinology and Metabolism|October 30, 2008
Hyperinsulinemia fails to augment ET-1 action in the skeletal muscle vascular bed in vivo in humansAmale A Lteif, Angie D Fulford, Robert V Considine, et al.
Diabetes/Metabolism Research and Reviews|May 8, 2002
Role of amylin in insulin secretion and action in humans: antagonist studies across the spectrum of insulin sensitivityKieren J Mather, Giancarlo Paradisi, Rosalind Leaming, et al.
Diabetes Care|April 28, 2005
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylureaDavid M Kendall, Matthew C Riddle, Julio Rosenstock, et al.
Pageof 3